Acotec Scientific Holdings Limited
先瑞達醫療科技控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6669)

VOLUNTARY ANNOUNCEMENT ENDOVENOUS RADIOFREQUENCY ABLATION SYSTEM RECEIVES U.S. FDA 510(K) CLEARANCE

This announcement is made by Acotec Scientific Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that on October 7, 2025, the Group's Endovenous Radiofrequency Ablation System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system consists of the Cedar™ Endovenous Radiofrequency Catheters and the Endovenous Radiofrequency Generator, which are used in combination for the treatment of lower extremity varicose veins caused by superficial venous reflux. The Company has entered into a distribution agreement with a member of the BSC Group for the distribution of this product in the United States. Moving forward, the BSC Group will begin commercializing the product in the U.S. market when appropriate.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET ENDOVENOUS RADIOFREQUENCY ABLATION SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By Order of the Board
Acotec Scientific Holdings Limited
Jing LI
Chairperson of the Board, Executive Director and Chief Executive Officer

Hong Kong, October 9, 2025

As at the date of this announcement, the executive Director is Ms. Jing LI, the non-executive Directors are Mr. Silvio Rudolf SCHAFFNER, Mr. Arthur Crosswell BUTCHER and Ms. June CHANG, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.